CN1512892A - 口服施用甲状旁腺激素和降钙素 - Google Patents

口服施用甲状旁腺激素和降钙素 Download PDF

Info

Publication number
CN1512892A
CN1512892A CNA028111613A CN02811161A CN1512892A CN 1512892 A CN1512892 A CN 1512892A CN A028111613 A CNA028111613 A CN A028111613A CN 02811161 A CN02811161 A CN 02811161A CN 1512892 A CN1512892 A CN 1512892A
Authority
CN
China
Prior art keywords
pth
calcitonin
effective amount
oral administration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028111613A
Other languages
English (en)
Chinese (zh)
Inventor
J���¶���
J·奥尔特
M·阿兹里亚
S·D·贝特曼
͵�
J·F·麦克劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1512892(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1512892A publication Critical patent/CN1512892A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028111613A 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素 Pending CN1512892A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
US60/295,169 2001-06-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910258008A Division CN101837120A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素

Publications (1)

Publication Number Publication Date
CN1512892A true CN1512892A (zh) 2004-07-14

Family

ID=23136525

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028111613A Pending CN1512892A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素
CN200910258008A Pending CN101837120A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910258008A Pending CN101837120A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素

Country Status (25)

Country Link
US (2) US20040186050A1 (https=)
EP (1) EP1397156B1 (https=)
JP (2) JP5073153B2 (https=)
KR (3) KR20090116836A (https=)
CN (2) CN1512892A (https=)
AT (1) ATE356631T1 (https=)
AU (2) AU2002344371B2 (https=)
BR (1) BRPI0209748B1 (https=)
CA (1) CA2446929C (https=)
CO (1) CO5540323A2 (https=)
CZ (1) CZ307145B6 (https=)
DE (1) DE60218842T2 (https=)
EC (1) ECSP034858A (https=)
ES (1) ES2282436T3 (https=)
HU (1) HU229613B1 (https=)
IL (2) IL158777A0 (https=)
MX (1) MXPA03011027A (https=)
NO (1) NO330093B1 (https=)
NZ (1) NZ529439A (https=)
PL (1) PL211976B1 (https=)
PT (1) PT1397156E (https=)
RU (1) RU2300392C2 (https=)
SK (1) SK287697B6 (https=)
WO (1) WO2002098453A2 (https=)
ZA (1) ZA200308625B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
CN105641686A (zh) 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
KR102163445B1 (ko) 2017-11-20 2020-10-07 주식회사 노브메타파마 Chp(사이클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
MX9401351A (es) * 1993-02-22 1994-08-31 Alza Corp Composiciones para suministro oral para agentes activos.
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
AU1189301A (en) 1999-10-29 2001-05-14 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物

Also Published As

Publication number Publication date
CA2446929C (en) 2013-04-09
BR0209748A (pt) 2004-07-27
KR20040007617A (ko) 2004-01-24
US20080119411A1 (en) 2008-05-22
KR101320817B1 (ko) 2013-10-21
JP2005500277A (ja) 2005-01-06
MXPA03011027A (es) 2004-03-19
KR20120065429A (ko) 2012-06-20
HUP0400120A3 (en) 2012-09-28
ZA200308625B (en) 2004-07-13
EP1397156A2 (en) 2004-03-17
HU229613B1 (en) 2014-03-28
RU2003136733A (ru) 2005-05-20
ES2282436T3 (es) 2007-10-16
JP2010189423A (ja) 2010-09-02
EP1397156B1 (en) 2007-03-14
NO20035133L (no) 2003-11-18
CZ307145B6 (cs) 2018-02-07
HUP0400120A2 (hu) 2005-04-28
CO5540323A2 (es) 2005-07-29
US8153587B2 (en) 2012-04-10
RU2300392C2 (ru) 2007-06-10
SK14752003A3 (sk) 2004-06-08
CN101837120A (zh) 2010-09-22
AU2002344371B2 (en) 2006-06-29
WO2002098453A3 (en) 2003-07-31
BRPI0209748B1 (pt) 2015-11-24
CA2446929A1 (en) 2002-12-12
IL158777A0 (en) 2004-05-12
WO2002098453A2 (en) 2002-12-12
PT1397156E (pt) 2007-05-31
JP5073153B2 (ja) 2012-11-14
AU2006225157B2 (en) 2009-04-23
PL364089A1 (en) 2004-12-13
DE60218842D1 (de) 2007-04-26
DE60218842T2 (de) 2007-12-20
NZ529439A (en) 2005-11-25
PL211976B1 (pl) 2012-07-31
KR20090116836A (ko) 2009-11-11
CZ20033232A3 (cs) 2004-06-16
US20040186050A1 (en) 2004-09-23
ATE356631T1 (de) 2007-04-15
NO330093B1 (no) 2011-02-14
ECSP034858A (es) 2004-01-28
SK287697B6 (sk) 2011-06-06
NO20035133D0 (no) 2003-11-18
AU2006225157A1 (en) 2006-10-19
IL158777A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
US8153587B2 (en) Orally administering parathyroid hormone and calcitonin
US9272040B2 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments
US8435946B2 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US20090264368A1 (en) Compositions for delivering parathyroid hormone and calcitonin
AU2002344371A1 (en) Orally administering parathyroid hormone and calcitonin
AU2002333443A1 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination